QUICK POLL
Which antihypertensive agents have been shown to reduce the risk of skin cancer?
Perspectives in Melanoma XII
2 - 4 October 2008
Scheveningen/The Hague, The Netherlands
Steigenberger Kurhaus Hotel
WHO SHOULD ATTEND
This educational activity is specifically designed for medical and surgical oncologists, dermatologists, researchers and other physicians, physicians-in-training and other healthcare professionals interested in and/or involved in the care of patients with melanoma and its consequences.
EDUCATIONAL OBJECTIVES
Upon completion of this activity, attendees should be able to:
- Discuss important aspects of the biology, pathogenesis and epidemiology of melanoma
- Describe the emerging technologies for biomarker development and the potential impact of biomarkers on treatment and management of melanoma
- Incorporate findings from recent clinical trials examining the role of adjuvant therapy into daily management of patients with melanoma
- Determine the utility of the sentinel node in clinical practice
- Describe emerging concepts and progress in the role of surgery and staging of melanoma
- Describe the role of the immune system in melanoma pathogenesis and identify immunological targets for therapy
- Identify currently available and investigational targeted agents for the management of
metastatic melanoma
Lionel Apetoh, PhD Philippe Autier, MD Ernest C. Borden, MD Marna Bouwhuis, MD Alexander M.M. Eggermont, MD, PhD Richard Essner, MD Keith T. Flaherty, MD Claus Garbe, MD Jeffrey E. Gershenwald, MD Helen Gogas, MD |
Tanja de Gruijl, PhD Nelleke Gruis, PhD Axel Hauschild, MD Mary J.C. Hendrix, PhD Peter Hersey, MD Ulrich Keilholz, MD John M. Kirkwood, MD Paul Lorigan, MD Michele Maio, MD, PhD James Mulé, MD |
Steven O’Day, MD Poulam Patel, MBBS, PhD James Pingpank, Jr., MD, FACS Dirk Schadendorf, MD Henrik Schmidt, MD Alan Spatz, MD Alexander van Akkooi, MD Christiane Voit, MD Jeffrey S. Weber, MD, PhD Jedd D. Wolchock, MD, PhD |
Thursday, 2 October 2008
8:30
Introductory address
Alexander M.M. Eggermont, MD, PhD
Session I: New insights into melanoma biology, pathogenesis and epidemiology
8:40
Targeting a novel embryonic pathway in melanoma
Mary J.C. Hendrix, PhD
9:00
Role of X-chromosome in pathogenesis
Alan Spatz, MD
9:20
Sun tanning in Iceland: Models for understanding melanoma epidemiology
Philippe Autier, MD
9:40
The GenoMEL report
Nelleke Gruis, PhD
10:00
Discussion
10:20
Break
Session II: Impact of emerging technologies for biomarker development
10:40
Gene profiling in melanoma
Alan Spatz, MD
11:00
Biomarker development and the role of proteomics
Dirk Schadendorf, MD
11:20
New technology for indentifying circulating tumor cells: Reliable at last?
Ulrich Keilholz, MD
11:40
Tumor infiltrating lymphocytes
Alan Spatz, MD
12:00
Discussion
12:20
Lunch
Session III: Abstract session I
14:20
Oral presentation of selected abstracts
Basic biology
O-001
Micro-RNA 203 and 200-family members are correlated with tumor progression in primary cutaneous melanoma
van den Oord, J
Prognostic factors
O-002
Shedding Cryptic Epitope (HU177) levels in Sera of advanced melanoma patients correlate with treatment response
Ott, P
O-003
Dissemination of melanoma cells beyond the sentinel lymph node (SLN) is the rule and not the exception
Ulmer, A
Emerging therapies
O-004
Abraxane and bevacizumab as first-line therapy in patients with stage IV melanoma
Boasberg, P
O-005
Phase 2 Study of LY573636-sodium, A novel anti-cancer compound with a unique mechanism of action, in patients with previously-treated unresectable or metastatic melanoma
Kirkwood, J
O-006
PV-10 Chemoablation of cutaneous and subcutaneous metastatic melanoma
Thompson, J
15:20
Break
Session IV: Adjuvant therapy
15:50
New biomarkers or prognostic factors in adjuvant therapy trial design
Henrik Schmidt, MD
16:10
Update on DeCOG interferon trials
Axel Hauschild, MD
16:30
Updated analysis and discussion of current EORTC trials
Alexander M.M. Eggermont, MD, PhD
16:50
Autoimmunity and adjuvant therapy revisited
Marna Bouwhuis, MD
17:10
HLA, CTLA-4 polymorphisms and autoimmunity
Helen Gogas, MD
17:30
STAT signaling and interferon response
John M. Kirkwood, MD
17:50
Roundtable discussion: Adjuvant therapy trial design and the role of biomarker studies
18:15
Adjourn
Friday, 3 October 2008
9:00
Introduction
Session V: Advances in staging and surgery
9:10
AJCC staging: Preview of the factors that may change in 2009
Jeffrey E. Gershenwald, MD
9:30
The sentinel node: Rotterdam criteria of tumor load and prognostic false positivity
Alexander van Akkooi, MD
9:50
Biological and immunological factors within the sentinel node
Richard Essner, MD
10:10
Alternative staging approaches: The role of ultrasound in prospective follow-up
Christiane Voit, MD
10:30
Discussion
10:50
Break
Session VI: Drug resistance in melanoma
11:10
Innovative models to determine chemoresistance
Claus Garbe, MD
11:30
New insights into mechanisms of drug resistance in melanoma
Peter Hersey, MD
11:50
Explorations of novel targets in melanoma to enhance drug effectiveness
Ernest C. Borden, MD
12:10
Discussion
12:30
Special address to the melanoma community
Valerie Guild, AiM at Melanoma Foundation
12:50
Lunch
Session VII: Abstract session II
14:00
Oral presentation of selected abstracts
Basic biology
O-007
Melanoma - T cell interaction in situ: relevance for immunotherapy
Tjin, E
Prognostic factors
O-008
Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene expression profile present at the tumor site
Louahed, J
Emerging therapies
O-009
Aranoza-based biochemotherapy in metastatic melanoma (MM) patients: Results of prospective randomized phase III study
Kharkevich, G
O-010
Clinical responses with modified TIL technology: Preliminary report
Schachter, J
O-011
Pilot clinical trial with autologous TriMix-Dendritic cell vaccine in patients with advanced melanoma, preliminary results
Neyns, B
14:50
Break
Session VIII: Immunotherapy
15:10
Novel improvements in dendritic cell-based vaccines for melanoma
James Mulé, MD
15:30
Enhancing the immune response to melanoma through CTLA-4 blockade
Jedd D. Wolchok, MD, PhD
15:50
Targeting novel immune regulating costimulatory molecules
Jeffrey Weber, MD
16:10
Regional immunological assessment of toll receptor agonists and cytokines
Tanja de Gruijl, PhD
16:30
Post chemotherapy effects and the initiation of immunity
Lionel Apetoh, PhD
16:50
Oral presentation of selected abstracts
Immunotherapy
O-012
Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable stage IIIc and IV melanoma
Coffin, R
O-013
Phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line in Chinese patients of advanced acral lentiginous melanoma (ALM)
Si, L
O-014
A phase I/II study to determine the feasibility and efficacy of the triple combination of Oblimersen (OBL), Abraxane (ABX), and Temozolomide (TMZ) in patients with metastatic melanoma and normal LDH.
Pavlick, A
O-015
Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma
Lebbé, C
17:30
Discussion
18:00
Adjourn
Saturday, 4 October 2008
8:15
Introduction
Session IX: Targeted therapies
8:20
Targeted Chemotherapy: Minimally invasive percutaneous hepatic perfusion
James Pingpank, Jr., MD
8:40
Targeting signaling pathways in melanoma
Keith T. Flaherty, MD
9:00
Targeting apoptosis in melanoma
Peter Hersey, MD
9:20
Targeting angiogenesis in melanoma
Paul Lorigan, MD
9:40
Epigenetic targets
Michele Maio, MD, PhD
10:00
Discussion
10:20
Break
Session X: Reports on important ongoing clinical trials
10:40
Introduction
10:50
Oblimersen
Claus Garbe, MD
11:00
Elesclomol
Steven J. O’Day, MD
11:10
Thymalfasin
Michele Maio, MD, PhD
11:20
CTLA-4 directed antibodies
Steven J. O’Day, MD
11:30
Nab-paclitaxel
Axel Hauschild, MD
11:40
Temozolomide
Poulam Patel, MBBS, PhD
11:50
Bevacizumab
Paul Lorigan, MD
12:00
Discussion
12:10
Closing remarks
12:15
Adjourn
REGISTRATION FEES
Regular Physician. . . . . . . . . . . €499
(If payment received by 24 September 2008)
Full/Onsite Physician . . . . . . . . €599
(If payment received after 24 September 2008)
Nurses/Residents/Fellows* . . . . .€199
*proof of eligibility must accompany registration
Pharmacists* . . . . . . . . . . . . . . €299
*proof of eligibility must accompany registration
EORTC Physician discount* . . . . - €100
*proof of eligibility must accompany registration
To Register: You may register online by 24 September 2008 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the Congress. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified. EORTC members receive an additional €100 off the published registration fees. Discount is for physicians only. To receive this discount you must register by telephone. Proof of eligibility may be verified.
Payment: To pre-register, registration and payment must be received no later than 24 September 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: A030.01 E Melanoma. An attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the announcement. Cancellation: For registration fees to be refunded, written notice of cancellation must be received by Imedex at meetings@imedex.com no later than 24 September 2008. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 24 September 2008.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this congress should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
Steigenberger Kurhaus Hotel
Gevers Deynootplein 30
2586 CK The Hague, The Netherlands
Tel.: +31 (0) 70 41 62636
Fax: +31 (0) 70 41 62646
www.kurhaus.nl
In the classical building of Kurhaus Hotel past and present uniquely converge. A rich and cultural past blends with a modern interior, present-day comfort and courteous hospitality. The Kurhaus hotel is in a class of its own with a prime seashore location and sand and dunes as far as they eye can see. Also nearby is royal The Hague, a magnificent city just behind the dunes, with countless opportunities for cultural activity, entertainment, shopping, relaxation and open air pursuits every conceivable amenity is close at hand or with walking distance.
The Kurhaus Hotel is easily accessible for people travelling by car, train or airplane. You can get to the hotel from Amsterdam Airport Schiphol and from Rotterdam Airport in less than an hour and from Brussels within two hours.
For the convenience of attendees, a limited number of rooms have been reserved until 17 September 2008 at a discounted rate. Several types of rooms are available. Please see the list below.
Superior town view room . . . . . . . . €233.76 per night single use
Executive town view room . . . . . . . €288.76 per night single use
Executive sea view room . . . . . . . . €328.76 per night single use
Rates quoted include tax, service charges and breakfast. This rate is not guaranteed outside the Congress dates or after 17 September 2008.
To reserve your room please contact the Kurhaus reservations department at +31 (0)70 4162630 or visit the hotel’s website at https://reservations.ihotelier.com/onescreenGroup.cfm?hotelID=4729.
To receive the group rate, callers must identify themselves as being with the Perspectives in Melanoma XII group. Internet users must enter the meeting attendee code: MELANOMA_ATT. Reservation requests received after 17 September 2008 may not be guaranteed the group rate.
Helpful Information on Train Transportation from Amsterdam Airport Schiphol to the Kurhaus Hotel
The Netherlands has an extensive and modern network of railways. Trains usually arrive on time and are considered comfortable and clean. The NS (Netherlands Railways) connects the big cities with intercity trains that only stop at the larger railway stations. From Amsterdam Airport Schiphol, there are two stations you may choose from to travel to The Hague.
Schiphol Airport to Den Haag Centraal (The Hague Central Station) - Departing from Amsterdam Airport Schiphol there are four trains an hour. A “sneltrein” (fast train or nonstop) train departs at: 29 and 59 minutes past the hour.
Schiphol Airport to Den Haag Hollands Spoor – the “intercity” train traveling nonstop departs at: 12, 15 and 45 minutes past the hour.
The Den Haag Centraal station is somewhat closer to the hotel than the Den Haage Hollands Spoor and it can be easier to catch a taxi from this location to the hotel. There is also a tram available from both stations to the hotel. Tram 9 toward Scheveningen can delivery you to Kurhaus Plein (square) which is located in front of the hotel.
Luggage: Luggage is carried directly onto the train by the passenger, with no additional baggage fees. Once on board, passengers may store their luggage in overhead compartments or sit/stand with their luggage in a storage area located at the rear of the cars.
Tickets: Ticket prices range from 7.30 € to 22.70 € depending on the ticket you purchase. Passengers may purchase tickets at the ticket service counters or in the ticket vending machines at the train area. Do not plan to purchase tickets directly from the conductor as this may increase the price.
CHAIRS
Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands
John M. Kirkwood, MD
University of Pittsburgh Medical Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
REGIONAL CO-CHAIRS
Alain Spatz, MD
Sir Mortimer B. Davis Jewish General Hospital & McGill University
Montreal, Quebec, Canada
Nelleke Gruis, PhD
Leiden University
Leiden, The Netherlands
INVITATION
Dear Colleague,
It is with great pleasure that we invite you to join us for Perspectives in Melanoma XII. This fall’s conference, 2-4 October 2008 in Scheveningen/The Hague, The Netherlands, promises to be an outstanding educational event.
With a wealth of new data in this rapidly evolving field, Perspectives in Melanoma XII is designed to provide you with a comprehensive overview of recent advances and rigorous discussions of the most current and controversial topics in the fields of melanoma, clinical research, and contemporary therapy. Led by authorities and current investigators in the field, the program will discuss several of the most promising and important on-going clinical trials. State-of-the-art presentations by experts in molecular biology, genetics, and immunology will provide a valuable educational experience for all melanoma-related disciplines.
We also know you will enjoy Scheveningen/The Hague with its opportunities for cultural activity, entertainment, shopping, relaxation and open air pursuits.
We look forward to welcoming you to Perspectives in Melanoma XII; your diverse perspectives and contributions add immeasurable value to this international program.
Sincerely,
Alexander M.M. Eggermont, MD, PhD
Chair
John M. Kirkwood, MD
Chair
CONGRESS LOCATION AND REGISTRATION:
Steigenberger Kurhaus Hotel
Gevers Deynootplein 30
2586 CK
The Hague, The Netherlands
Tel.: +31 (0) 70 41 62636
Fax: +31 (0) 70 41 62646
www.kurhaus.nl
ITALIAN PARTICIPANTS:
Fargo International Meetings & Conventions SRL has been appointed as the official agency for government authorization for Italian participants. You may contact them directly at:
Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137
Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078
IMPORTANT DATES:
Abstract Notifications Mailed:
14 August 2008
Abstract Presenter Registration Deadline: 17 September 2008
Regular RegistrationDeadline: 24 September 2008
EORTC Melanoma Group Program: 1 October 2008
Presentation Dates: 2-4 October 2008
THE VALUE
- “Nice conference – I’ll be back”
- “Very good meeting”
- “Fantastic well-organized conference”
THE CLINICAL IMPACT
95% of attendees have changed their knowledge of screening, diagnosis, and prevention
100% of attendees have shared information they learned at the conference with a colleague or colleagues
95% of attendees would recommend this conference to someone in their same position
ORGANIZER
Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED. In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician. Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society. ©2008 Imedex<sup>®</sup>, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
CORPORATE SUPPORT
Platinum Gold
Silver
|
Jointly With
Several options are available to companies interested in supporting this congress. For more information, please contact Imedex at +1 (770) 751 7332 or by email at CME@imedex.com.
SOCIETIES, ASSOCIATIONS AND FOUNDATIONS
This Congress is endorsed by the following societies, associations and foundations:
|
